EGFR and non-small cell lung carcinoma: The most widely studied of these is the epidermal growth factor receptor (EGFR), with the small-molecule inhibitor gefitinib being the first quinazoline derivative to be approved for the treatment of Non-Small Cell Lung Cancer [17,18,19,20,21].